AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8867274
Drug: Diclofenac (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (2 x 50 mg capsules/day)
Trial: 3931465
Drug: Glyburide once
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide once daily
Trial: 3931465
Drug: Glyburide twice
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide twice daily
Trial: 3931465
Drug: Chlorpropamide once
RxNorm normalized name: Chlorpropamide
DrugBank: Chlorpropamide (DB00672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpropamide once daily
Trial: 31278117
Drug: Whey protein-based
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein-based nutritional supplement enriched with leucine and vitamin D
Trial: 23907291
Drug: Neoadjuvant single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant single agent doxorubicin
Trial: 19196813
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg x kg(‐1) human alpha(1)‐AT (Prolastin)
Trial: 3814462
Drug: Nimodipine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (both doses)
Trial: 2789070
Drug: Aspirin 600
RxNorm normalized name: aspirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600 mg four times daily (9 doses)
Trial: 2789070
Drug: Aspirin 600
RxNorm normalized name: aspirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600 mg four times daily with ethamsylate 500 mg before each dose
Trial: 25690515
Drug: Safer-drinking strategies
RxNorm normalized name: Safe-Guard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safer-drinking strategies endorsed and implemented (e.g., eating prior to and during drinking, spacing drinks, reducing alcohol consumption)
Trial: 24428305
Drug: Conventional weight‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional weight‐based dosing of GH (0.04 mg/kg/day)
Trial: 24428305
Drug: GH dosing
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH dosing titrated to an IGF‐I target of 0 SDS (IGF0T)
Trial: 24428305
Drug: GH dosing
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH dosing titrated to an IGF‐I target of +2 SDS (IGF2T)
Trial: 23097066
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg subcutaneously every six months
Trial: 19419595
Drug: Ziprasidone (80-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (80-120 mg/d)
Trial: 9541034
Drug: Smoked cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked cocaine (up to 405 mg over 5 hours daily) for 4 days
Trial: 9541034
Drug: Drug-free period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free period (2 days before and after cocaine administration)
Trial: 8017448
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg at bedtime
Trial: 2525415
Drug: Continuous hepatic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hepatic artery and intravenous infusion of FUDR (IA/IV group; 21 patients)
Trial: 2525415
Drug: Hepatic artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic artery infusion alone (IA group; 23 patients)
Trial: 23688934
Drug: SYNERGY ½
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYNERGY ½ dose
Trial: 21411610
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) ingestion (30 to 80 g/h, not exceeding 8%) during exercise
Trial: 26876309
Drug: Donepezil 10
RxNorm normalized name: donepezil 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg daily
Trial: 9351079
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (6 g/day; n = 18)
Trial: 3812100
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of Azatadine
Trial: 11287022
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) hCG administration
Trial: 11287022
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) hCG administration
Trial: 11287022
Drug: Both SC
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both SC and IM hCG administration
Trial: 30224390
Drug: Low-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose interleukin-2 (aldesleukin; dose range 0.3-3×10^6 IU)
Trial: 17581445
Drug: TF-CBT +
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TF-CBT + sertraline
Trial: 15608430
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 or 4 mg daily
Trial: 10458396
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid treatment with improved hygiene
Trial: 7822521
Drug: Low-dose cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporine (2.5 mg/kg/day, adjusted to 5.0 mg/kg/day)
Trial: 7822521
Drug: Etretinate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate (0.5 mg/kg/day, adjusted to 0.75 mg/kg/day)
Trial: 7822521
Drug: Cyclosporine replaced
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine replaced by topical dithranol (anthralin)
Trial: 7822521
Drug: Etretinate followed
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretinate followed by topical dithranol
Trial: 25819853
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg once daily plus clopidogrel 75 mg daily for 12 months
Trial: 25819853
Drug: Dose-adjusted vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted vitamin K antagonist (VKA) once daily
Trial: 15551207
Drug: Combination vaccine
RxNorm normalized name: Hepatitis vaccine combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination vaccine (RSV cpts‐248/404 and PIV3‐cp45), 10(5) plaque‐forming units of each per 0.5‐mL dose
Trial: 15551207
Drug: Monovalent PIV3
RxNorm normalized name: rotavirus, monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent PIV3 vaccine
Trial: 15551207
Drug: Monovalent RSV
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent RSV cpts‐248/404 vaccine
Trial: 15551207
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (combination and monovalent)
Trial: 9407422
Drug: Lowest tertile
RxNorm normalized name: textiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest tertile of baseline proteinuria (< 2.5 g/24 hr)
Trial: 9407422
Drug: Middle tertile
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle tertile of baseline proteinuria (2.5 to 4.3 g/24 hr)
Trial: 9407422
Drug: Highest tertile
RxNorm normalized name: textiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest tertile of baseline proteinuria (> 4.3 g/24 hr)
Trial: 8504651
Drug: Aminophylline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (4 mg/kg bolus followed by 2.5 mg/kg every 6 hrs x three doses, then 1.5 mg/kg every 6 hrs)
Trial: 1742507
Drug: Ranitidine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine therapy
Trial: 2890820
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sleeping with the bed-head raised and ranitidine therapy
Trial: 26614597
Drug: ibandronate 1
RxNorm normalized name: ibandronate 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibandronate 1 mg/month
Trial: 26614597
Drug: risedronate oral
RxNorm normalized name: risedronate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risedronate oral 2.5 mg/day
Trial: 14600927
Drug: Adenosine (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (140 micro g/kg/min) with low level exercise protocol (300 MBq and 700 MBq Tc‐99m tetrofosmin for stress and rest respectively)
Trial: 10573515
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (13‐15 mg/kg daily)
Trial: 6859584
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg morphine epidurally
Trial: 6859584
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg morphine epidurally
Trial: 6859584
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg morphine epidurally
Trial: 31349042
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus adjuvant radiation therapy (S+ART)
Trial: 31349042
Drug: Surgical monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical monotherapy (SM)
Trial: 31119692
Drug: Esaxerenone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaxerenone (5 mg) administered in the fasting state as a single oral dose
Trial: 31119692
Drug: Esaxerenone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaxerenone (5 mg) administered in the postprandial state as a single oral dose
Trial: 31119692
Drug: Fasting intravenous
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting intravenous administration of esaxerenone
Trial: 31119692
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of fasting versus postprandial oral administration of esaxerenone
Trial: 25491433
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER 4 mg/day
Trial: 18381905
Drug: DMXB-A (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMXB-A (lower dose)
Trial: 2178941
Drug: Parenteral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral estrogen (polyestradiol phosphate 80 or 160 mg i.m. monthly)
Trial: 760745
Drug: Biperidine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperidine (5 mg) administered intravenously to five patients after a single dose of PPZ-enanthate i.m.
Trial: 760745
Drug: Oral PPZ
RxNorm normalized name: APAP 325/CTM 4/PPZ 25/PHENYLTOLOX 25MG C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PPZ treatment in fourteen patients with addition of biperidine or orphenadine given for 3 weeks in fixed oral doses.
Trial: 760745
Drug: Concomitant antiparkinson
RxNorm normalized name: ANTIPARKINSON AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant antiparkinson therapy with PPZ.
Trial: 25405562
Drug: Low MTV
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low MTV (<37.2 mL)
Trial: 23193746
Drug: 3% minoxidil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% minoxidil lotion (MNX)
Trial: 23193746
Drug: Combined 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 3% minoxidil and 0.1% finasteride lotion (MFX)
Trial: 18607268
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum and fructooligosaccharides (synbiotic preparation)
Trial: 1922206
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens 1.25 mg per day
Trial: 1922206
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol 2 mg per day
Trial: 1922206
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 0.1 mg twice a week
Trial: 7065386
Drug: Infusion solutions
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion solutions warmed to body temperature and operation theatre temperature raised to 22-24 degrees C
Trial: 31900273
Drug: Tai chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai chi exercise (12-week programme, 60 min per session, twice weekly)
Trial: 31900273
Drug: Balance and
RxNorm normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Sunsolve MD Balance and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance and postural control training (12-week programme, 60 min per session, twice weekly)
Trial: 24074720
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=17), home based physical therapy exercise program without isokinetic.
Trial: 22372774
Drug: Triple-combination therapy
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-combination therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide (OM/AML/HCTZ)
Trial: 19732641
Drug: Warmed levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed levobupivacaine (20 mL of levobupivacaine 5 mg/mL + 0.005 mg/mL epinephrine at 40 degrees C)
Trial: 19732641
Drug: Room-temperature levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room-temperature levobupivacaine (20 mL of levobupivacaine 5 mg/mL + 0.005 mg/mL epinephrine at 25 degrees C)
Trial: 17263634
Drug: IDV/r 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDV/r 800/100 mg bid
Trial: 15106814
Drug: Trandolapril 2
RxNorm normalized name: trandolapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 2 mg (T)
Trial: 15106814
Drug: Verapamil SR/trandolapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil SR/trandolapril 180/2 mg (V + T)
Trial: 11805389
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (125 IU/kg, once weekly)
Trial: 11805389
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (250 IU/kg, once weekly)
Trial: 9746884
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (20 million KIU given over 30 h)
Trial: 3258815
Drug: tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiaprofenic acid tablets 300 mg twice daily
Trial: 3258815
Drug: tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiaprofenic acid sustained action (SA) capsules 600 mg once daily
Trial: 3258815
Drug: indomethacin sustained
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: indomethacin sustained release (SR) capsules 75 mg once daily
Trial: 3258815
Drug: tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiaprofenic acid SA capsules
Trial: 3258815
Drug: indomethacin SR
RxNorm normalized name: Indomethacin SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indomethacin SR capsules
Trial: 3258815
Drug: tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiaprofenic acid tablets
Trial: 27600363
Drug: Acute naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute naltrexone treatment
Trial: 25841041
Drug: Amisulpride 38.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride 38.3 mg/d
Trial: 25841041
Drug: Aripiprazole 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 1.4 mg/d
Trial: 25841041
Drug: Asenapine 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 0.9 mg/d
Trial: 25841041
Drug: Chlorpromazine 38.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine 38.9 mg/d
Trial: 25841041
Drug: Clozapine 30.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 30.6 mg/d
Trial: 25841041
Drug: Haloperidol 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 0.7 mg/d
Trial: 25841041
Drug: Quetiapine 32.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 32.3 mg/d
Trial: 25841041
Drug: Risperidone 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 0.4 mg/d
Trial: 25841041
Drug: Sertindole 1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole 1.1 mg/d
Trial: 25841041
Drug: Ziprasidone 7.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 7.9 mg/d
Trial: 25841041
Drug: Zotepine 13.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotepine 13.2 mg/d
Trial: 24067385
Drug: Subcutaneous white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous white adipose tissue (SWAT) biopsies pre-intervention
Trial: 24067385
Drug: Subcutaneous white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous white adipose tissue (SWAT) biopsies post-intervention
Trial: 19226352
Drug: Dairy intervention
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy intervention group (IG: n = 39) receiving approximately 1200 mg of calcium and 7.5 microg of vitamin D(3) per day via fortified dairy products and attending biweekly nutrition counselling sessions
Trial: 19226352
Drug: Calcium-supplemented group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-supplemented group (SG: n = 26) receiving a total of 1200 mg calcium per day
Trial: 8222489
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cefdinir alone
Trial: 8222489
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cefdinir with two tablets of iron ion concomitantly
Trial: 8222489
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cefdinir with two tablets of iron ion preparation 3 hours later
Trial: 3978009
Drug: Weight-related dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-related dose of buprenorphine, age, sex, body weight, duration of anaesthesia, dose of droperidol or thiopentone
Trial: 30853329
Drug: Vibration and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration and cold gel pack application
Trial: 25820842
Drug: Ayahuasca (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (a psychedelic preparation containing N,N-dimethyltryptamine)
Trial: 21172601
Drug: Statistically significant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistically significant results for efficacy, private funding, primary harms outcome, and anti-infective, antineoplasmatic, or immunosuppressive agents
Trial: 11795467
Drug: Heat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatment of whole blood in vitro for 2 hours at different temperatures (up to 41 degrees C)
Trial: 7846203
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg IV)
Trial: 30051155
Drug: Attention Control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention Control Condition (CC)
Trial: 28342090
Drug: Standard patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard patch
Trial: 25277390
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (210 IU and 420 IU)
Trial: 25277390
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of ins‐asp (0.12 IU/kg/24 h)